FDA Approved New Therapy for Advanced Kidney Cancer
The drug combination provides a new option for patients with advanced renal cell carcinoma who have previously undergone immunotherapy.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Should the FDA approve new drug combinations based primarily on progression-free survival data?
The FDA has approved the combination of belzutifan and lenvatinib for adults with advanced renal cell carcinoma with a clear cell component. This treatment is specifically indicated for patients who have already been treated with a PD-1 or PD-L1 inhibitor.
Why it matters
This approval introduces a new combination therapy that showed improved progression-free survival compared to standard treatments for patients whose cancer has progressed after initial immunotherapy. It provides a necessary alternative for those managing advanced disease.
The LITESPARK-011 trial enrolled 747 patients to compare the combination of belzutifan and lenvatinib against cabozantinib. The combination therapy demonstrated a median progression-free survival of 14.6 months, compared to 10.6 months in the cabozantinib group.
The players
FDA
The federal agency responsible for regulating pharmaceuticals and public health in the United States.
The details
The treatment works by pairing belzutifan, which targets the HIF-2alpha pathway, with lenvatinib, a multi-kinase inhibitor that blocks proteins involved in tumor growth and blood vessel formation. Efficacy was determined via blinded independent central review using RECIST v1.1 criteria. Patients in the combination group received 20 mg of lenvatinib and 120 mg of belzutifan daily, and they must be monitored for potential toxicities including embryo-fetal risks.
Timeline
September 24, 2026: The FDA approved the belzutifan and lenvatinib combination.
Health Landscape
This approval marks a significant expansion of treatment options for renal cell carcinoma, which has historically relied on various targeted therapies and immunotherapies. It extends the research findings observed within the LITESPARK clinical trial program for kidney cancer treatments.
Patients with advanced renal cell carcinoma should consult their oncologist to determine if this new combination therapy is appropriate based on their prior treatment history. Because of the risk of embryo-fetal toxicity, patients should discuss all safety warnings and reproductive health considerations with their physician.
The takeaway
The combination of belzutifan and lenvatinib offers a new progression-free survival benefit for specific advanced kidney cancer cases. Patients and their medical teams should review the full prescribing information, particularly the boxed warning regarding embryo-fetal toxicity.
Further reading
For more information on current treatment standards and ongoing research, visit Cancer.
Live Poll
Should the FDA approve new drug combinations based primarily on progression-free survival data?
